HIV pre-exposure prophylaxis (HIV-PrEP) is effective in reducing the likelihood of HIV acquisition in HIV-negative people at high risk of exposure. Guidelines recommend testing for sexually transmitted infections (STIs) before starting, and periodically on PrEP, including bacterial infections, HIV, hepatitis C virus, and, for those who are non-immune, hepatitis B virus. Diagnosed infections can be promptly treated to reduce onward transmission. HTLV-1 is not mentioned; however, it is predominantly sexually transmitted, causes adult T-cell leukaemia/lymphoma (ATL) or myelopathy in 10% of those infected, and is associated with an increased risk of death in those without any classically HTLV-associated condition. The 2021 WHO Technical Report on HTLV-1 called for the strengthening of global public health measures against its spread. In this scoping review, we, therefore, (1) discuss the epidemiological context of HIV-PrEP and HTLV-1 transmission; (2) present current knowledge of antiretrovirals in relation to HTLV-1 transmission prevention, including nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and integrase strand transfer inhibitors (INSTIs); and (3) identify knowledge gaps where data are urgently required to inform global public health measures to protect HIV-PrEP users from HTLV-1 acquisition. We suggest that systematic seroprevalence studies among PrEP-using groups, including men who have sex with men (MSM), people who inject drugs (PWIDs), and female sex workers (FSWs), are needed. Further data are required to evaluate antiretroviral efficacy in preventing HTLV-1 transmission from studies, animal models, and clinical cohorts. PrEP delivery programmes should consider prioritizing the long-acting injectable INSTI, cabotegravir, in HTLV-1 endemic settings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103472 | PMC |
| http://dx.doi.org/10.3389/fmed.2022.881547 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
M-Sec promotes the accumulation of intracellular HTLV-1 Gag puncta and the incorporation of Env into viral particles.
PLoS Pathog
January 2025
Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
We have demonstrated that the cellular protein M-Sec promotes the transmission of human T-cell leukemia virus type 1 (HTLV-1) in vitro and in vivo. Here, we show how HTLV-1 utilizes M-Sec for its efficient transmission. HTLV-1-infected CD4+ T cells expressed M-Sec at a higher level than uninfected CD4+ T cells.
View Article and Find Full Text PDFViral Oncogenesis: Synergistic Role of Genome Integration and Persistence.
Viruses
December 2024
Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), 00149 Rome, Italy.
Persistence is a strategy used by many viruses to evade eradication by the immune system, ensuring their permanence and transmission within the host and optimizing viral fitness. During persistence, viruses can trigger various phenomena, including target organ damage, mainly due to an inflammatory state induced by infection, as well as cell proliferation and/or immortalization. In addition to immune evasion and chronic inflammation, factors contributing to viral persistence include low-level viral replication, the accumulation of viral mutants, and, most importantly, maintenance of the viral genome and reliance on viral oncoprotein production.
View Article and Find Full Text PDFIsolation of Viral Biofilms From HTLV-1 Chronically Infected T Cells and Integrity Analysis.
Bio Protoc
December 2024
Infectious Disease Research Institute of Montpellier (IRIM), UMR 9004 CNRS, University of Montpellier, Montpellier, France.
The human T-lymphotropic virus type-1 (HTLV-1) is an oncogenic retrovirus that predominantly spreads through cell-to-cell contact due to the limited infectivity of cell-free viruses. Among various modes of intercellular transmission, HTLV-1 biofilms emerge as adhesive structures, polarized at the cell surface, which encapsulate virions within a protective matrix. This biofilm is supposed to facilitate simultaneous virion delivery during infection.
View Article and Find Full Text PDFDeclining trend of HTLV-1 among organ/ tissue donors in Iranian Tissue Bank between 2014-2021.
Retrovirology
December 2024
Iranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- HTLV-1 is linked to serious health issues like Adult T-cell Leukemia/Lymphoma and HAM/TSP; thus, screening potential organ donors for the virus is vital due to high transmission risks, particularly in kidney transplant recipients.
- A study at the Iranian Tissue Bank from 2014 to 2021 found that 3% of 3,814 potential organ/tissue donors tested positive for HTLV-1, with rates significantly dropping from 6% to 0.5% over the years.
- Females showed a higher positivity rate (4%) than males (2%), and donors with brain death had a much lower infection rate (0.2%) compared to those with circulatory death (4%).
Characterization of HTLV-1 Infectious Molecular Clone Isolated from Patient with HAM/TSP and Immortalization of Human Primary T-Cell Lines.
Viruses
November 2024
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA.
Article Synopsis
- HTLV-1 is linked to diseases like adult T-cell leukemia and HTLV-1-associated myelopathy, prompting researchers to isolate a molecular clone from a patient with HAM/TSP.
- This clone exhibits unique genetic features and viral mRNA patterns, indicating a potential connection to the development of HAM/TSP.
- The study finds that while direct infection of primary T cells with HTLV-1 clones leads to limited cell growth, transmission from dendritic cells enhances long-term proliferation and supports latent infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!